20% of national population has dyslipidemia – most popular treatment

against it includes statins, which are effective and have very limited risk
of adverse effects
Dyslipidemia Landscape

4% of total dyslipidemia
Most popular treatment But patients may experience
includes taking statins since some kind of intolerance1
to statins
20% of national
population has
dyslipidemia
• Effective
• Limited risk of adverse Ezetimibe is an option
effects

Product X is able to reduce LDL to a much lower level in

comparison to statins

1. Half of them are intolerant and the other half have low efficacy 0
Source: Case
18% of the population could take product X – as its cost of treatment
per month is estimated on USD 200 vs statins that range from USD 5-20
we should expect no price war but face a strong adoption barrier

Product X
18%1 of USD 200/month
national
population VS
could use
product X Statins
USD 5-20/month

No price war

1. 90% of dyslipidemia patients could take product X 1

Source: Case
If the treatment were to reach the market with a USD 200 p/month
cost, MDs would be willing to prescribe it to ~ 7,5% of patients but only
1% of patients would be in economical conditions to purchase it

Price range % of patients to

(USD p/month of receive
treatment) a prescription
50 – 75 25%

75 – 100 20%

100 – 200 10% ~7,5%1 of patients to receive a

product X prescription at USD
200 – 300 5% 200

300 – 400 4%
Only 1% of patients with
economical conditions to
purchase the product at USD 200
p/month

1. Linear estimation between segments 2

Source: Case
However, government programs might be a solution – the public system
takes from 2 to 3 years to decide whether to include a product into its
programs after a pharmaeconomical study has been done
Universe of Patients to receive a product X prescription

6,5% 1%1

Government programs2 may add 6,5 pp of patients

2-3 years required to have a final decision of inclusion (or not) on

the public system
1. Assumption: those able to purchase it receive a prescription and actually purchase it
2. Private Health Insurance programs, Employers and PBM may also be added depending
on the country’s pharmaceutical market 3
Source: Case
SPFC should focus on statins intolerance patients and government and
private insurance programs – lower costs would allow to overcome the
high price adoption barrier
Key Takeaways & Recommendations

Key Takeaways Recommendations

• 4% of dyslipidemia patients have • Focus on statins intolerance patients
intolerance or low efficacy with statins
• Prioritize the pharmaeconomical study
• Government takes 2-3 years to include or
not the product on the public system after
the pharmaeconomical study is ready • Focus on government and private insurance
programs1
• Product X is able to reduce LDL to a much
lower level in comparison to statins • Innovate on production process to lower
costs
• Its price may be a strong adoption barrier,
but no price war should be expected

1. Private Health insurance, Employers and PBM may also be added depending on the
country’s pharmaceutical market 4
Source: Case